All In Biotech

Drug Trial Radar · NCT02608450

A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25)

A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris

Last checked: Nov 19, 2026Latest source record: Nov 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 708 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

708

Actual

Start

Jan 21, 2016

Primary completion

Apr 11, 2018

Study completion Apr 11, 2018

Sponsor

Lead sponsor
Cassiopea SpAIndustry
Sponsor type
Industry
First posted
Nov 18, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 9 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to determine the safety and efficacy of CB-03-01 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

  • CB-03-01 cream, 1%Drug

    CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.

  • Vehicle creamDrug

    Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA)Time frame: Week 12
  2. Change From Baseline in Non-inflammatory Lesion CountsTime frame: Baseline and Week 12
  3. Change From Baseline in Inflammatory Lesion CountsTime frame: Baseline and Week 12

Locations

54 sites in 3 countries. Site status is shown where the registry gives one.

  • Gary M. Petrus, MD PA

    Little Rock, Arkansas

  • Center For Dermatology Clinical Research, Inc.

    Fremont, California

  • Vitiligo & Pigmentation Institute of Southern California

    Los Angeles, California

  • San Diego Sports Medicine and Family Health Center

    San Diego, California

  • Rady Childrens Hospital, Pediatric and Adolescent Dermatology

    San Diego, California

  • Southern California Dermatology

    Santa Ana, California

  • Clinical Science Institute

    Santa Monica, California

  • Memorial Research Medical Clinic dba / Orange County Research Center

    Tustin, California

  • Horizons Clinical Research Center, LLC

    Denver, Colorado

  • Site 0190

    Boca Raton, Florida

  • Study Protocol, Inc.

    Boynton Beach, Florida

  • Site 0196

    Miami, Florida

  • Site 0197

    Miami, Florida

  • Site 0198

    Miami, Florida

  • Site 0199

    Miami, Florida

  • Site 0191

    Miami, Florida

  • Site 0192

    Miami, Florida

  • Site 0195

    Miami, Florida

  • Tory Sullivan, M.D., P.A.

    North Miami Beach, Florida

  • Meridien Research

    St. Petersburg, Florida

  • MOORE Clinical Research, Inc.

    Tampa, Florida

  • MedaPhase, Inc.

    Newnan, Georgia

  • Site 0152

    Carmel, Indiana

  • The Indiana Clinical Trials Center

    Plainfield, Indiana

  • Henry Ford Health System

    Detroit, Michigan

  • MediSearch Clinical Trials

    Saint Joseph, Missouri

  • The Center for Dermatology, Cosmetic & Laser Surgery

    Mount Kisco, New York

  • DermResearch Center of New York, Inc.

    Stony Brook, New York

  • Wake Research Associates

    Raleigh, North Carolina

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina

  • Oregon Dermatology and Research Center

    Portland, Oregon

  • The Pennsylvania State University and the Milton S. Hershey Medical Center

    Hershey, Pennsylvania

  • Omega Medical Research

    Warwick, Rhode Island

  • Greenville Dermatology, LLC

    Greenville, South Carolina

  • International Clinical Research - Tennessee LLC

    Murfreesboro, Tennessee

  • Tennessee Clinical Research Center

    Nashville, Tennessee

  • Westlake Dermatology Clinical Research Center

    Austin, Texas

  • Bellaire Dermatology Associates

    Bellaire, Texas

  • J&S Studies, Inc.

    College Station, Texas

  • The University of Texas Health Science Center at Houston

    Houston, Texas

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.